Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography.
about
The Production Processes and Biological Effects of Intravenous ImmunoglobulinRecovery and purification process development for monoclonal antibody productionAnti-Human Platelet Antigen-1a Immunoglobulin G Preparation Intended to Prevent Fetal and Neonatal Alloimmune ThrombocytopeniaPorcine parvovirus removal using trimer and biased hexamer peptides.Minipool caprylic acid fractionation of plasma using disposable equipment: a practical method to enhance immunoglobulin supply in developing countries.Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's diseasePathogen Safety of a New Intravenous Immune Globulin 10% Liquid.Influence of peptide ligand surface density and ethylene oxide spacer arm on the capture of porcine parvovirus.In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparationsImmunomodulation of human B cells following treatment with intravenous immunoglobulins involves increased phosphorylation of extracellular signal-regulated kinases 1 and 2.The role of isoagglutinins in intravenous immunoglobulin-related hemolysis.A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance.Purification of polyclonal antibodies from Cohn fraction II + III, skim milk, and whey by affinity chromatography using a hexamer peptide ligand.Structural study on immunoglobulin G solution after pasteurization with and without stabilizer.HPLC fingerprinting approach for raw material assessment and unit operation tracking for IVIG production from Cohn I+II+III fraction.Dedicated removal of immunoglobulin (Ig)A, IgM, and Factor (F)XI/activated FXI from human plasma IgG.Not all intravenous immunoglobulins are the same: appropriate selection in patients with compromised renal function.Binding Performance of Human Intravenous Immunoglobulin and 20()-7-Ethylcamptothecin
P2860
Q26752540-F636099E-8487-4F18-9DCF-706542C02275Q28288423-AC394FAB-D4F1-48C5-BD6C-E52A5365A927Q33435351-6679806C-46E9-41BD-9724-8DB5674396F3Q33959628-5C7A4A15-479F-4CD0-B77F-1EA2037E5595Q35125865-4ED3B55E-7EDB-4B4A-8C6F-4402A7213746Q36462680-11274099-FE57-4865-87F9-CA7DD2A1EAF2Q37737558-05FA981D-1C75-4674-B818-E472D4596CA4Q39050550-E9BD64FD-601B-4759-9ABF-BF67B5E9C296Q39273058-AC81A44A-C391-493D-B76F-F6C95D4013F6Q39952567-4F178A27-2BC4-4455-9EA9-CDF0CAA4E484Q40736607-CE75B258-1D4B-4228-93F3-A16A2545EDF0Q42997771-56764CDA-DC53-4862-B7AD-5721322D3BA8Q44864973-0956194C-3DD3-49FE-8A74-B9CA22681B95Q46750680-15461FC9-BA4E-4A50-B0C0-55139D08E0C5Q48095460-F712F884-5F31-4FCA-B288-B9092F25DF64Q50967516-96C27F93-6B78-478D-B867-B249B83D6B47Q53604233-D2D0E4AF-12C5-4812-A25F-F4CBC1709B61Q58691864-A2E9DFEF-EE37-4FAE-97AD-43E52FE7E1FA
P2860
Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Properties of a new intravenou ...... ate and column chromatography.
@en
Properties of a new intravenou ...... ate and column chromatography.
@nl
type
label
Properties of a new intravenou ...... ate and column chromatography.
@en
Properties of a new intravenou ...... ate and column chromatography.
@nl
prefLabel
Properties of a new intravenou ...... ate and column chromatography.
@en
Properties of a new intravenou ...... ate and column chromatography.
@nl
P2093
P2860
P1433
P1476
Properties of a new intravenou ...... ate and column chromatography.
@en
P2093
C Schreiner
K M Remington
P2860
P304
P356
10.1046/J.1423-0410.2003.00285.X
P577
2003-04-01T00:00:00Z